Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) EBITDA (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of EBITDA data on record, last reported at -$24.8 million in Q4 2023.

  • For Q4 2023, EBITDA rose 14.25% year-over-year to -$24.8 million; the TTM value through Dec 2023 reached -$152.6 million, down 189.18%, while the annual FY2025 figure was -$218.7 million, 30.67% down from the prior year.
  • EBITDA reached -$24.8 million in Q4 2023 per CGEM's latest filing, up from -$38.6 million in the prior quarter.
  • Across five years, EBITDA topped out at $239.7 million in Q2 2022 and bottomed at -$56.6 million in Q1 2023.
  • Average EBITDA over 4 years is -$6.7 million, with a median of -$21.1 million recorded in 2021.
  • The widest YoY moves for EBITDA: up 1553.13% in 2022, down 11145.31% in 2022.
  • A 4-year view of EBITDA shows it stood at -$36.1 million in 2020, then rose by 9.91% to -$32.5 million in 2021, then rose by 10.91% to -$28.9 million in 2022, then rose by 14.25% to -$24.8 million in 2023.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$24.8 million in Q4 2023, -$38.6 million in Q3 2023, and -$32.6 million in Q2 2023.